AAV-based ABCA4 gene therapy (Biogen)

N/A

Report date: 2025/01/26 18:11:34

Base Information

Drug NameAAV-based ABCA4 gene therapy (Biogen)
Drug Alias NameAAV-based ABCA4 gene therapy (NightstaRx)AAV-based ABCA4 gene therapy (Oxford University Innovation)NSR-ABCA4
ClassificationBiologics
Mechanisms of ActionRetinal-specific phospholipid-transporting ATPase ABCA4 stimulants
TargetsRetinal-specific phospholipid-transporting ATPase ABCA4
Therapy Area/IndicationsStargardt Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOxford University Innovation Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiogen Inc
Inactive CompaniesNightstarTx LtdOxford University Innovation Ltd
Active IndicationsStargardt Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A